organization · Reporting owner
Metuchen Therapeutics, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Petros Pharmaceuticals, Inc.
Report date March 23, 2021 · Filed October 21, 2021
Section 16 reporting ended · disclosed 2021-10-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2020 Filed Dec 28, 2020 19:46 UTC Amendment | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock, par value $0.0001 per share | 3,395,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-021618 · doc1.xml · nonDerivative · entry 1 SHULMAN JOHN D · CIK 0001208886 · Director · 10% owner Juggernaut Partners III GP, L.P. · CIK 0001835421 · 10% owner Juggernaut Partners III GP, Ltd. · CIK 0001835433 · 10% owner METP Holdings LLC · CIK 0001836319 · 10% owner JCP III SM AIV, L.P. · CIK 0001835386 · 10% owner Metuchen Therapeutics, LLC · CIK 0001836798 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,395,964 F1 · shares: This amended Form 4 is being filed to add Reporting Persons and to adjust the number of securities acquired to account for the same. F2 · price: See Note (1) in Exhibit 99.1. F3 · ownership.nature: See Note (2) in Exhibit 99.1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.